Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions

dc.creatorFerreira, Marcelo U.
dc.creatorSousa, Tais Nobrega de
dc.creatorRangel, Gabriel W.
dc.creatorJohansen, Igor C.
dc.creatorCorder, Rodrigo M.
dc.creatorLadeia-Andrade, Simone
dc.creatorGil, José Pedro
dc.date2021-09-05T14:23:18Z
dc.date2021-09-05T14:23:18Z
dc.date2021
dc.date.accessioned2023-09-26T22:22:55Z
dc.date.available2023-09-26T22:22:55Z
dc.identifierFERREIRA, Marcelo U. et al. Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions. International Journal for Parasitology: Drugs and Drug Resistance, v. 15, p. 9- 24, 2021.
dc.identifier2211-3207
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/48987
dc.identifier10.1016/j.ijpddr.2020.12.001
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8878521
dc.descriptionEmerging antimalarial drug resistance may undermine current efforts to control and eliminate Plasmodium vivax, the most geographically widespread yet neglected human malaria parasite. Endemic countries are expected to assess regularly the therapeutic efficacy of antimalarial drugs in use in order to adjust their malaria treatment policies, but proper funding and trained human resources are often lacking to execute relatively complex and expensive clinical studies, ideally complemented by ex vivo assays of drug resistance. Here we review the challenges for assessing in vivo P. vivax responses to commonly used antimalarials, especially chloroquine and primaquine, in the presence of confounding factors such as variable drug absorption, metabolism and interaction, and the risk of new infections following successful radical cure. We introduce a simple modeling approach to quantify the relative contribution of relapses and new infections to recurring parasitemias in clinical studies of hypnozoitocides. Finally, we examine recent methodological advances that may render ex vivo assays more practical and widely used to confirm P. vivax drug resistance phenotypes in endemic settings and review current approaches to the development of robust genetic markers for monitoring chloroquine resistance in P. vivax populations.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.rightsopen access
dc.subjectPlasmodium vivax
dc.subjectResistência às drogas
dc.subjectCloroquina
dc.subjectPrimaquina
dc.subjectEstudos clínicos
dc.subjectEnsaios ex vivo
dc.subjectMarcadores moleculares
dc.subjectPlasmodium vivax
dc.subjectDrug resistance
dc.subjectChloroquine
dc.subjectPrimaquine
dc.subjectClinical studies
dc.subjectEx vivo assays
dc.subjectMolecular markers
dc.titleMonitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions
dc.typeArticle


Este ítem pertenece a la siguiente institución